S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
OTCMKTS:CYDY

CytoDyn (CYDY) Stock Price, News & Analysis

$0.16
0.00 (0.00%)
(As of 04/19/2024 ET)
Today's Range
$0.15
$0.16
50-Day Range
$0.15
$0.26
52-Week Range
$0.13
$0.42
Volume
662,955 shs
Average Volume
1.35 million shs
Market Capitalization
$153.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
CYDY stock logo

About CytoDyn Stock (OTCMKTS:CYDY)

CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

CYDY Stock Price History

CYDY Stock News Headlines

CytoDyn Says FDA Lifts Hold On Leronlimab
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
CytoDyn Announces FDA Has Lifted Clinical Hold
CytoDyn Inc CYDY
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Investors file another lawsuit against CytoDyn
CytoDyn Announces Webcast to Provide Company Update
CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO
CytoDyn (OTC: CYDY)
See More Headlines
Receive CYDY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CytoDyn and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/15/2024
Today
4/21/2024
Fiscal Year End
5/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:CYDY
Previous Symbol
NASDAQ:CYDY
CUSIP
23283M101
Fax
N/A
Employees
12
Year Founded
N/A

Profitability

Net Income
$-79,820,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$270,000.00
Book Value
($0.12) per share

Miscellaneous

Free Float
985,823,000
Market Cap
$153.89 million
Optionable
Not Optionable
Beta
0.16
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Cyrus Arman M.B.A. (Age 42)
    Ph.D., Senior Vice President of Business Operations
    Comp: $451.17k
  • Dr. Jacob P. Lalezari M.D. (Age 64)
    CEO & Member of Scientific Advisory Board
  • Mr. Mitchell Cohen (Age 67)
    Interim Chief Financial Officer
  • Mr. Tyler Blok (Age 36)
    Executive Vice President of Legal Affairs & Secretary
  • Dr. Scott Hansen Ph.D.
    Head of Research & Basic Science
  • Mr. Joseph Meidling
    Executive Director of Clinical Operations
  • Ms. Cristina De Leon
    Investors

CYDY Stock Analysis - Frequently Asked Questions

How have CYDY shares performed in 2024?

CytoDyn's stock was trading at $0.1950 at the start of the year. Since then, CYDY shares have decreased by 20.5% and is now trading at $0.1550.
View the best growth stocks for 2024 here
.

Are investors shorting CytoDyn?

CytoDyn saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 4,680,600 shares, a decline of 8.4% from the March 15th total of 5,107,100 shares. Based on an average trading volume of 2,871,500 shares, the days-to-cover ratio is presently 1.6 days.
View CytoDyn's Short Interest
.

How were CytoDyn's earnings last quarter?

CytoDyn Inc. (OTCMKTS:CYDY) posted its quarterly earnings data on Monday, April, 15th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter.

What other stocks do shareholders of CytoDyn own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CytoDyn investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), NVIDIA (NVDA), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Vaxart (VXRT), Nokia Oyj (NOK), Pfizer (PFE), Sorrento Therapeutics (SRNE) and Moderna (MRNA).

How do I buy shares of CytoDyn?

Shares of CYDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:CYDY) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners